You are here

Roche

AbbVie, Roche to seek broader market for leukemia drug after trial success

AbbVie, Roche to seek broader market for leukemia drug after trial success

BioPharma Dive

clinical trials

chronic lymphocytic leukemia

Flag link:

FDA Clears Biotech Drug Copycats, But Buying Them Isn’t So Easy

FDA Clears Biotech Drug Copycats, But Buying Them Isn’t So Easy

Bloomberg

Flag link:

Samsung Bioepis first to secure EMA backing for Herceptin biosimilar

Samsung Bioepis first to secure EMA backing for Herceptin biosimilar

BioPharma Dive

Samsung Bioepis

Flag link:

FDA adds two Roche studies to its growing list of partial clinical holds in wake of Keytruda deaths

FDA adds two Roche studies to its growing list of partial clinical holds in wake of Keytruda deaths

Endpoints

clinical trials

Flag link:

Halozyme, Inovalon, and Teva Soared This Week: Can They Go Higher?

Halozyme, Inovalon, and Teva Soared This Week: Can They Go Higher?

Motley Fool

Teva Pharmaceutical

Unitedhealthcare Group

Bristol-Myers Squibb

Flag link:

FDA commish cheers on biosimilars as Amgen, Allergan score OK for knockoff of Roche’s Avastin

FDA commish cheers on biosimilars as Amgen, Allergan score OK for knockoff of Roche’s Avastin

Endpoints

Flag link:

FDA says Tecentriq won't lose its bladder cancer nod despite phase 3 failure, Roche reports

FDA says Tecentriq won't lose its bladder cancer nod despite phase 3 failure, Roche reports

Fierce Pharma

clinical trials

Flag link:

Roche gets hit with another big R&D setback as a prospective AMD blockbuster flops in PhIII

Roche gets hit with another big R&D setback as a prospective AMD blockbuster flops in PhIII

Endpoints

Flag link:

An accurate analysis of the differences between Swiss companies Roche and Novartis

An accurate analysis of the differences between Swiss companies Roche and Novartis

GoInPharma

Flag link:

Parkinson's Now a Hot Therapeutic Area: What's Up Lately?

Parkinson's Now a Hot Therapeutic Area: What's Up Lately?

Yahoo/Zacks.com

Parkinson's Disease

Teva Pharmaceutial

Adamas Pharmaceuticals

Flag link:

Best Pharma Stocks Based on R&D Spending

Best Pharma Stocks Based on R&D Spending

Motley Fool

Flag link:

Under fire from Shire, Roche grabs the VIP lane for top drug prospect emicizumab

Under fire from Shire, Roche grabs the VIP lane for top drug prospect emicizumab

Endpoints

Flag link:

Personal turf is ‘out,’ community workplaces are ‘in’ at the new Roche neighborhood

Personal turf is ‘out,’ community workplaces are ‘in’ at the new Roche neighborhood

Endpoints

Flag link:

An analysis of 2017 first half for pharmaceutical industry

An analysis of 2017 first half for pharmaceutical industry

GoInPharma

pharma industry

Bristol-Myers Squibb

Flag link:

Lawmakers dig into 'skyrocketing' MS costs with probe into 7 drugmakers

Lawmakers dig into 'skyrocketing' MS costs with probe into 7 drugmakers

Fierce Pharma

multiple sclerosis

Teva Pharmaceutical

Flag link:

Roche, Mimetas develop “gut-on-a-chip” tech for drug-testing

Roche, Mimetas develop “gut-on-a-chip” tech for drug-testing

Drug Delivery Business News

drug development

Flag link:

New target could yield treatment for Alzheimer's, ALS and more

New target could yield treatment for Alzheimer's, ALS and more

Fierce Biotech

drug development

Alzheimer's disease

Flag link:

Drug developers face increasingly risky tightrope walk between top-line results and hard data

Drug developers face increasingly risky tightrope walk between top-line results and hard data

Endpoints

drug development

clinical trials

late stage data

Flag link:

Pharma's giants, new and old, tell more tales than their numbers show

Pharma's giants, new and old, tell more tales than their numbers show

Fierce Pharma

Bristol-Myers Squibb

Flag link:

The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results

The 2017 report card so far: Big Biotech largely trading up as pharma posts mixed results

Fierce Pharma

Bristol-Myers Squibb

Flag link: